Zestril Related Published Studies
Well-designed clinical trials related to Zestril (Lisinopril)
Pleural effusions, water balance mediators and the influence of lisinopril after completion Fontan procedures. [2009.07]
Irbesartan improves arterial compliance more than lisinopril. [2009]
Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.05]
Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis. [2008.02]
Bioequivalence evaluation of two brands of lisinopril tablets by in vitro comparative dissolution test and in vivo bioequivalence test. [2008]
A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. [2007.10]
Effects of candesartan and lisinopril on the fibrinolytic system in hypertensive patients. [2007.06]
Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow-up. [2007.03]
Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. [2007.02]
Clinical effects produced by a standardized herbal medicinal product of Hibiscus sabdariffa on patients with hypertension. A randomized, double-blind, lisinopril-controlled clinical trial. [2007.01]
Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension. [2006.08]
A randomized, masked, cross-over trial of lisinopril for inflammatory macular edema. [2006.04]
Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. [2006.03]
Impact of chronic lisinopril therapy on left atrial volume versus dimension in chronic organic mitral regurgitation. [2006.02]
Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. [2006.02]
Bioequivalence evaluation of two brands of lisinopril tablets (Lisotec and Zestril) in healthy human volunteers. [2005.11]
Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. [2005.08]
Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. [2005.06]
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. [2005.04.06]
Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. [2005.02]
Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. [2005.01]
Clarithromycin suspension: bioequivalence studies on two different strengths. [2004.09]
Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials. [2004.09]
Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). [2004.07]
Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. [2004.06]
Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. [2004.06]
Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. [2004.05]
Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. [2004.03.15]
Prospective and randomized study of the antihypertensive effect and tolerability of three antihypertensive agents, losartan, amlodipine, and lisinopril, in hypertensive patients. [2004.01]
Evaluation of the bioequivalence and pharmacokinetics of two lisinopril tablet formulations after single oral administration in healthy volunteers. [2004]
Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. [2003.11]
A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. [2003.10]
Blood pressure- and pulse pressure-lowering effects, trough:peak ratio and smoothness index of telmisartan compared with lisinopril. [2003.10]
Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension. [2003.09.01]
Well-designed clinical trials possibly related to Zestril (Lisinopril)
Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment. [2009.07]
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. [2009.06]
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. [2009.05.11]
Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease. [2009.05]
Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients. [2009.04]
Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). [2009.02]
Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. [2009.01]
Controlling hypertension and hypotension immediately post stroke (CHHIPS)--a randomised controlled trial. [2009.01]
Brain imaging findings predict blood pressure response to pharmacological treatment. [2008.12]
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. [2008.11.25]
A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction. [2008.11]
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.10]
Cerebrovascular support for cognitive processing in hypertensive patients is altered by blood pressure treatment. [2008.07]
Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-3 trial. [2008.02]
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.01.28]
Impact of medication packaging on adherence and treatment outcomes in older ambulatory patients. [2008.01]
Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. [2007.11]
Sex-specific effects of AGT-6 and ACE I/D on pulse pressure after 6 months on antihypertensive treatment: the GenHAT study. [2007.11]
ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial. [2007.07]
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. [2007.04]
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. [2007.01]
Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. [2007]
Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2006.11.13]
Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring. [2006.10]
Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2006.09]
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. [2006.09]
Effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and their combination on microalbuminuria in normotensive patients with type 2 diabetes. [2006.07]
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. [2006.05.09]
Impaired capacity for stimulated fibrinolysis in primary hypertension is restored by antihypertensive therapy. [2006.04]
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. [2006.02.07]
Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. [2005.11]
Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. [2005.06.28]
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2005.06.27]
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2005.04.25]
Intraindividual blood pressure responses to angiotensin-converting enzyme inhibition and angiotensin receptor blockade. [2005.01]
Gender difference in the response to an angiotensin-converting enzyme inhibitor and a diuretic in hypertensive patients of African descent. [2004.06]
A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN6257616]. [2004.03.25]
Effect of statin therapy added to ACE-inhibitors on blood pressure control and endothelial functions in normolipidemic hypertensive patients. [2003.12]
Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2003.11]
Other research related to Zestril (Lisinopril)
Refractory hypotension and ECG changes in a case of nicorandil and lisinopril overdose and role of vasopressor in management. [2009.08]
Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study. [2009.04]
Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. [2009.01]
Optimization of hydrogels for transdermal delivery of lisinopril by Box-Behnken statistical design. [2009]
Comparison of some physical parameters of whole and scored lisinopril and lisinopril/hydrochlorthiazide tablets. [2008.11]
Development and validation of LC-MS method for the determination of lisinopril in human plasma and its application in a bioequivalence study. [2008.11]
Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. [2008.10.31]
Production and in vitro characterization of lisinopril-loaded nanoparticles for the treatment of restenosis in stented coronary arteries. [2008.10]
[Effects of lisinopril on diabetic peripheral neuropathy: experiment with rats] [2008.09.16]
Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. [2008.09]
Effects of fixed combination of lisinopril plus hydrochlorothiazide on regression of left ventricular hypertrophy in patients with essential hypertension: an opened, multi-centre, prospective clinical trial. [2008.08]
Case reports: lisinopril-induced erythroderma in an 85-year-old male. [2008.02]
Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.02]
Fixed combination lisinopril plus hydro-chlorothiazide in the treatment of essential arterial hypertension: an opened, multi-centre, prospective clinical trial. [2007.11]
Influence of tablet splitting on content uniformity of lisinopril/hydrochlorthiazide tablets. [2007.11]
Lisinopril-induced acute pancreatitis. [2007.09]
Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension. [2007.06.01]
Adult lisinopril ingestions reported to Texas poison control centers, 1998 2005. [2007.06]
Efficacy of lisinopril in migraine prophylaxis--an open label study. [2007.06]
A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. [2007.05]
Lisinopril in paediatric medicine: a retrospective chart review of long-term treatment in children. [2007.03]
Pediatric lisinopril ingestions reported to Texas poison control centers. [2007.02]
A case of fatal necrotizing pancreatitis: complication of hydrochlorothiazide and lisinopril therapy. [2007.02]
Effect of lisinopril on rat liver tissues in L-NAME induced hypertension model. [2007.02]
Other possibly related research studies
Effect of antihypertensive treatment on retinal microvascular changes in hypertension. [2008.08]
Hyponatremia associated with tolterodine therapy. [2008.06.01]
Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. [2008.05.06]
Primary hyperparathyroidism presenting with severe hypertension in a middle aged Nigerian--a case report. [2008.03]
|
